GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » Buyback Yield %

TaiMed Biologics (ROCO:4147) Buyback Yield % : -7.53 (As of Apr. 30, 2025)


View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

TaiMed Biologics's current buyback yield was -7.53%.


TaiMed Biologics Buyback Yield % Historical Data

The historical data trend for TaiMed Biologics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics Buyback Yield % Chart

TaiMed Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.03 -0.06 -0.17 -7.01

TaiMed Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -6.97 -6.77 -7.56 -7.01

Competitive Comparison of TaiMed Biologics's Buyback Yield %

For the Biotechnology subindustry, TaiMed Biologics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Buyback Yield % falls into.


;
;

TaiMed Biologics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

TaiMed Biologics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 1645.325) / 23485.052
=-7.01%

TaiMed Biologics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1645.325) / 23485.052
=-7.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


TaiMed Biologics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of TaiMed Biologics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiMed Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others. It earns revenue from sale of medicines and by providing contract testing and development services for biopharmaceuticals.

TaiMed Biologics Headlines

No Headlines